CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz. by Neary, MG et al.
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A) B)
C) D)Difference in ENG AUC for each statistically significant SNP.
Values represented as mean (standard deviation)
ENG and EFV pharmacokinetics for each statistically significant genotype.
Values given as median (interquartile range)
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CYP2B6 516G>T was associated with:
• 43% lower log10 ENG Cmin (P=0.003, β=-0.102) in TT compared to GG patients
• 34% lower log10 ENG AUC0-24 weeks (P=0.008, β=-0.106) in TT compared to GG patients
CYP2B6 983T>C was associated with:
• 37% lower log10 ENG Cmax (P=0.003, β=-0.237) in CT compared to TT patients
• 20% lower log10 ENG AUC0-24 weeks (P=0.016, β=-0.158) in CT compared to TT patients
EFV plasma concentration (C12-14hrs) was:
• 76% higher in TT patients for CYP2B6 516G>T compared to GG patients
• 69% higher in CT patients for CYP2B6 983T>C compared to TT patients
- The etonogestrel (ENG) implant is an effective hormonal contraceptive method
commonly used in sub-Saharan Africa.
- Drug-drug interactions between contraceptive progestins and antiretrovirals,
specifically efavirenz (EFV), continue to be a significant barrier to contraceptive
use among women living with HIV.
- ENG concentrations were previously demonstrated to be 82% lower at week
24 in women receiving efavirenz (EFV) based antiretroviral therapy (ART)
compared to women not receiving ART. (1)
- We investigated a genetic contribution to this previously observed drug-drug
interaction through studying the following SNPs in the same group of women:
CYP2B6 516G>T, 983T>C and 15582C>T, CYP3A4 293A>G, NR1I2 63396C>T,
ABCB1 4036A>G and 3435C>T.
- CYP2B6 is the primary metaboliser of EFV and CYP3A4 is the primary
metabolizer of ENG. NR1I2 encodes the pregnane X receptor, a transcriptional
regulator of multiple CYPs including CYP2B6 and CYP3A4. ABCB1 encodes the
P-glycoprotein receptor a membrane bound transporter of many endogenous
substrates and xenobiotics, including EFV.
Patient characteristics and genotype frequencies for each 
SNP.
Values given as median (interquartile range) or % 
This study demonstrates a relationship between CYP2B6
polymorphisms and alterations in ENG pharmacokinetics when
ENG implants are combined with EFV.
We hypothesize that this relationship is mediated by an
indirect effect of reduced EFV metabolism by CYP2B6, resulting
in higher EFV concentrations. Supratherapeutic EFV
concentrations may induce CYP3A4 to a greater extent,
resulting in lower ENG exposure.
These results are consistent with previously observed
associations between SNPs in CYP2B6 and lower levonorgestrel
implant pharmacokinetics when combined with EFV. (4)
Further study is required to confirm the mechanism of action
of this association.
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Ethics: All study procedures approved by the University of Pittsburgh (PRO14010195), the
Joint Clinical Research Centre, and Uganda National Council of Science and Technology (HS
1618). This study followed the Declaration of Helsinki and was registered at clinicaltrials.gov
(NCT02082652).
Study Population: 19 patients receiving EFV (600mg daily) based ART. Exclusionary criteria
included but was not limited to HIV RNA >400 copies/mL and participants receiving any
medication that was contraindicated for use with ENG or EFV. Participants in the EFV group
had a copper intrauterine device inserted prior to study initiation to minimise the risk of
unintended pregnancy in the event of ENG contraceptive failure.
Sample Collection: Study visits occurred at 1, 4, 12 and 24 weeks post implant placement.
Blood samples were taken in order to determine ENG concentration at each study visit. For
EFV a single timed blood sample was taken twice before implant insertion and 4, 12 and 24
weeks post implant insertion.
Pharmacokinetic Parameters: Pharmacokinetic parameters included in this analysis were area
under the concentration time curve from entry to 24 weeks for ENG (AUC0-24wk), maximum
ENG concentration (Cmax) and minimum ENG concentration (Cmin). AUC was calculated using
the trapezoidal rule. EFV concentrations were taken 12-14 hours post dose (C12-14h).
ENG/EFV Concentration Quantification: ENG concentrations were quantified using
HPLC/mass spectrometry, EFV concentrations were quantified using HPLC, utilising validated
methods. (2)(3)
Genotyping: Genotyping was performed by allelic discrimination real-time PCR using
TaqMan® SNP Genotyping assays for selected candidate SNPs.
Statistical Analysis: Univariate linear regression analysis was conducted with a P ≤ 0.20
classed as significant. All variables significant in univariate analysis were included in a
multivariate backwards linear regression analysis P ≤ 0.05.
Statistically significant associations between variables and ENG pharmacokinetic parameters.
